ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children with Primary Hyperoxaluria Type 1
Phase of Trial: Phase III
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Lumasiran (Primary)
- Indications Primary hyperoxaluria
- Focus Registrational; Therapeutic Use
- Acronyms ILLUMINATE-B
- Sponsors Alnylam Pharmaceuticals
- 31 Aug 2019 Planned number of patients changed from 8 to 20.
- 15 Apr 2019 According to an Alnylam Pharmaceuticals media release, the Company expects to report initial ILLUMINATE-B results in mid-2020.
- 15 Apr 2019 Status changed from not yet recruiting to recruiting, according to an Alnylam Pharmaceuticals media release.